23:18 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Aneurysm Mouse experiments suggest that inhibiting HDAC9 or the long non-coding RNA (lncRNA) MALAT1 could help treat thoracic aortic aneurysms. In aortic tissue samples from thoracic aortic aneurysm patients, levels of HDAC9 were higher...
20:01 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); B cell lymphoma Patient sample, cell culture and mouse studies suggest HDAC inhibitors could help treat patients with B cell precursor ALL expressing gene fusions involving MEF2D . Levels of...
07:00 , Apr 4, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Trifluoromethyloxadiazole (TFMO)-containing compounds to identify class IIa histone deacetylase (HDAC) inhibitors TFMO-containing compounds could be used as research compounds to guide...
07:00 , Apr 4, 2013 |  BC Innovations  |  Cover Story

Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylase s, 1 a not-so-well-understood subset of the target family that...
08:00 , Jan 27, 2011 |  BC Innovations  |  Cover Story

HDACs get complex

Cellzome AG has reported a chemical proteomic method for determining the selectivity of HDAC inhibitors. The approach makes it possible, for the first time, to determine the effects of an inhibitor on HDACs as components...
01:20 , Mar 6, 2007 |  BC Extra  |  Clinical News

Researchers publish Foxp3 mechanism

Researchers from the University of Pennsylvania published a mechanism in The Proceedings of the National Academy of Sciences by which the forkhead family protein Foxp3 helps to repress the transcription of T cells in vivo....